The use of intralesional epidermal growth factor in the treatment of diabetic foot ulcers
- 31 December 2023
- journal article
- research article
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (6) , 607-612
Abstract
Aims: The mitogenic and cell protective effects of epidemal growth factor (EGF) in wound healing stimulate the growth, re-covering the surface of the wound area. In this research we tried to elucidate the effectiveness of intradermal EGF application on wound healing in diabetic foot ulcers regarding the fact that EGF can accelerate the formation of skin cover layer on the infected surface, even in relatively ischemic cases. Methods: The data of 68 patients who applied to our institution’s orthopedics and wound care outpatient clinic with the diagnosis of diabetic foot ulcer, who underwent wound care, debridement and follow-up were retrospectively analyzed. All of the patients included in this study were classified as Wagner Stage III and Stage IV diabetic foot ulcers and were followed up with standard wound care. EGF application was initiated if there was not enough bleeding on the wound borders and defect floor after debridement. Results: The rate of patients with 50% or more granulation in the second week of treatment in the groups was 35.7% (n=10) in the standard treatment group, it was 60% (n=24) in the EGF group (pKeywords
This publication has 23 references indexed in Scilit:
- Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcersBMC Pharmacology and Toxicology, 2013
- The Relationship of Sugar to Population-Level Diabetes Prevalence: An Econometric Analysis of Repeated Cross-Sectional DataPLOS ONE, 2013
- Granulation Response and Partial Wound Closure Predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated With Recombinant Human Epidermal Growth FactorDiabetes Care, 2013
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Lower extremity amputations - a review of global variability in incidenceDiabetic Medicine, 2011
- The Evidence for the Use of Growth Factors and Active Skin Substitutes for the Treatment of Non-Infected Diabetic Foot Ulcers (DFU): A Health Technology Assessment (HTA)Experimental and Clinical Endocrinology & Diabetes, 2011
- Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closureInternational Wound Journal, 2009
- Intralesional injections of Citoprot‐P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputationInternational Wound Journal, 2007
- Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot woundsInternational Wound Journal, 2006
- Human Epidermal Growth Factor Enhances Healing of Diabetic Foot UlcersDiabetes Care, 2003